<qa>  How many patients are planned to remain on the dose throughout the trial?Secondary objectives are to evaluate pharmacokinetic, immunogenicity, overall and best clinical response, changes in tumor marker levels, survival and biologicalimmune responses to EMD 521873. A total of 78 patients are planned. Patients will remain on the dose throughout the trial. It is intended to administer 3 cycles 21 d each, or until progression or a xxx line therapy becomes necessary. 